ArticleTheranostics2017
A Unique Recombinant Fluoroprobe Targeting Activated Platelets Allows
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Self-Assembled Nanoparticles with Kynureninase-Fc Fusion Protein and Pheophorbide A for Photodynamic Immunometabolic Cancer Therapy.Journal of functional biomaterials · 2026Article
- Optical theranostics in ischemic heart disease: from molecular insights to clinical translation.Theranostics · 2025Review
- Arterial Thrombosis in Acute Respiratory Infections: An Underestimated but Clinically Relevant Problem.Journal of clinical medicine · 2024Review
- Thrombus-specific/responsive biomimetic nanomedicine for spatiotemporal thrombolysis and alleviation of myocardial ischemia/reperfusion injury.Journal of nanobiotechnology · 2022Article
- In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications.Journal of nanobiotechnology · 2022Review
- Platelets in Multiple Sclerosis: Early and Central Mediators of Inflammation and Neurodegeneration and Attractive Targets for Molecular Imaging and Site-Directed Therapy.Frontiers in immunology · 2021Review
- Targeting Contrast Agents With Peak Near-Infrared-II (NIR-II) Fluorescence Emission for Non-invasive Real-Time Direct Visualization of Thrombosis.Frontiers in molecular biosciences · 2021Review
- Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis.Frontiers in cardiovascular medicine · 2021Review
- Monoclonal antibody-based molecular imaging strategies and theranostic opportunities.Theranostics · 2020Review
- Dual-Targeted Theranostic Delivery of miRs Arrests Abdominal Aortic Aneurysm Development.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging.Theranostics · 2017Article
- miR-3150b-3p Promotes Vascular Smooth Muscle Cell Injury by Targeting ARL5B.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress in pharmaceutical development is highly-dependent on preclinical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.